Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (GB:0R1B)
LSE:0R1B
Holding GB:0R1B?
Track your performance easily
0R1B Stock Chart & Stats
Day’s Range― - ―
52-Week Range$145.10 - $252.25
Previous CloseN/A
Volume3.66K
Average Volume (3M)3.34K
Market Cap
$21.69B
Enterprise Value$33.27B
Total Cash (Recent Filing)$4.90B
Total Debt (Recent Filing)$6.51B
Price to Earnings (P/E)13.6
Beta0.56
Next Earnings
Jan 30, 2025EPS Estimate
3.41Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)11.07
Shares Outstanding145,719,350
10 Day Avg. Volume2,874
30 Day Avg. Volume3,344
Standard Deviation0.09
R-Squared0.00603
Alpha-0.00674
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)5.80
P/FCF Ratio6.30
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
$225.37Price Target Upside49.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Biogen News
PremiumMarket News
QQQ ETF News, 1/14/2025
Bulls Say, Bears Say
Bulls Say
Acquisitions And Growth CapacityBIIB completed two high-profile acquisitions (RETA, Hi-Bio) while management indicates they hold capacity for an additional ~$8B-$10B in transactions over the next two years.
Pipeline And Product DevelopmentThe immunology pipeline, especially dapirolizumab pegol in SLE, is seen as intriguing and bears watching for future potential.
Regulatory MilestonesBiogen partner Eisai's request for the EMA's CHMP to reexamine the MAA for lecanemab in amyloid-positive early Alzheimer's disease has paid off with a positive recommendation.
Bears Say
Deal ConcernsAnalyst is not convinced that SAGE deal is the right deal for BIIB or that it could happen at the current offer price.
Pipeline And Earnings GrowthBIIB experienced multiple pipeline failures, and upcoming programs are not expected to address earnings growth concerns in the near term.
Revenue ChallengesNearly 60% of the top-line in 2024 will be driven by MS products that face numerous headwinds, including competition and loss of exclusivity.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.14% Insiders
34.91% Mutual Funds
0.17% Other Institutional Investors
32.51% Public Companies and Individual Investors
0R1B FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest share price was $145.10 and its highest was $252.25 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $21.69B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Jan 30, 2025 which is in 15 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Oct 30, 2024. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $3.772 by $0.308.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.225 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.41.
How many shares outstanding does Biogen have?
Biogen has 145,719,350 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $4.08 in its last earnings report, beating expectations of $3.772. Following the earnings report the stock price went down -1.27%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in GB:0R1B
---
Biogen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$225.37 (49.89% Upside)
$225.37 (49.89% Upside)
Blogger Sentiment
Bullish
GB:0R1B Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $17.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.47%
12-Months-Change
Fundamentals
Return on Equity
10.47%
Trailing 12-Months
Asset Growth
0.43%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
0R1B Company Deck
---
0R1B Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Biogen's earnings call highlighted significant progress in new product launches and a promising late-stage pipeline, resulting in raised financial guidance for the year. However, challenges persist in core revenue streams like MS and SPINRAZA, with infrastructure issues impacting LEQEMBI's U.S. performance.Read More>---
0R1B Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
0R1B Stock 12 Month Forecast
Average Price Target
$225.37
▲(49.89% Upside)
Technical Analysis
Biogen
―
Amgen
―
Vertex Pharmaceuticals
―
Gilead Sciences
―
Regeneron
―
Merck & Company
―
Incyte
―
Best Analysts Covering 0R1B
1 Year
1 Year Success Rate
12/39 ratings generated profit
1 Year Average Return
-6.95%
reiterated a buy rating 27 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -6.95% per trade.
---